As of 2024-12-15, the EV/EBITDA ratio of Vertex Pharmaceuticals Inc (VRTX) is 25.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Vertex's latest enterprise value is 113,013.89 mil USD. Vertex's TTM EBITDA according to its financial statements is 4,440.00 mil USD. Dividing these 2 quantities gives us the above Vertex EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 15.4x - 19.0x | 15.9x |
| Forward P/E multiples | 20.8x - 35.0x | 24.9x |
| Fair Price | 290.74 - 642.23 | 381.68 |
| Upside | -37.3% - 38.5% | -17.7% |
| Date | EV/EBITDA |
| 2024-12-13 | 25.45 |
| 2024-12-12 | 25.48 |
| 2024-12-11 | 25.72 |
| 2024-12-10 | 25.77 |
| 2024-12-09 | 26.05 |
| 2024-12-06 | 25.36 |
| 2024-12-05 | 25.23 |
| 2024-12-04 | 25.47 |
| 2024-12-03 | 25.06 |
| 2024-12-02 | 25.57 |
| 2024-11-29 | 25.71 |
| 2024-11-27 | 25.50 |
| 2024-11-26 | 25.65 |
| 2024-11-25 | 25.34 |
| 2024-11-22 | 24.71 |
| 2024-11-21 | 24.68 |
| 2024-11-20 | 24.73 |
| 2024-11-19 | 24.54 |
| 2024-11-18 | 25.64 |
| 2024-11-15 | 25.57 |
| 2024-11-14 | 26.63 |
| 2024-11-13 | 27.24 |
| 2024-11-12 | 26.98 |
| 2024-11-11 | 27.66 |
| 2024-11-08 | 28.53 |
| 2024-11-07 | 27.70 |
| 2024-11-06 | 27.19 |
| 2024-11-05 | 27.55 |
| 2024-11-04 | 25.98 |
| 2024-11-01 | 25.88 |
| 2024-10-31 | 26.16 |
| 2024-10-30 | 26.11 |
| 2024-10-29 | 25.84 |
| 2024-10-28 | 26.19 |
| 2024-10-25 | 26.26 |
| 2024-10-24 | 25.93 |
| 2024-10-23 | 25.82 |
| 2024-10-22 | 26.10 |
| 2024-10-21 | 26.29 |
| 2024-10-18 | 26.57 |
| 2024-10-17 | 27.48 |
| 2024-10-16 | 26.82 |
| 2024-10-15 | 26.65 |
| 2024-10-14 | 26.68 |
| 2024-10-11 | 26.50 |
| 2024-10-10 | 26.17 |
| 2024-10-09 | 25.70 |
| 2024-10-08 | 25.18 |
| 2024-10-07 | 24.58 |
| 2024-10-04 | 24.97 |